DEF 14A: Orchestra BioMed Holdings Sets Date for 2024 Annual Stockholders Meeting

Orchestra BioMed Holdings will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Summary

• Orchestra BioMed Holdings, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, at 11:00 a.m. Eastern Time.
• Stockholders of record as of April 26, 2024, are eligible to vote.
• The meeting will cover the election of two Class I directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and any other business that may properly come before the meeting.
• The Board recommends voting for the election of Eric A. Rose, M.D. and Jason Aryeh as Class I directors and for the ratification of Ernst & Young LLP's appointment.
• The company is providing proxy materials over the Internet to reduce environmental impact and costs.
• As of the record date, there were 35,786,497 shares of common stock outstanding.
• The election of directors requires a plurality of the vote, while the ratification of the accounting firm requires the affirmative vote of a majority of the shares present and entitled to vote.
• Stockholders can vote online, by phone, or by mail before the meeting or online during the meeting.
• The company's Board consists of seven directors, with Class I directors' terms expiring at this meeting.
• The company's Audit Committee consists of Ms. Connealy, Mr. Aryeh and Mr. Pacitti.
• The company's Compensation Committee consists of Dr. Fain, Dr. Rose and Mr. Pacitti.
• The company's Nominating and Corporate Governance Committee consists of Mr. Aryeh, Dr. Fain and Dr. Rose.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The positive aspects include the company's focus on innovation and growth, while the negative aspects include the risks associated with the company's business and industry.

Positives

• The company is embracing virtual meeting technology to provide expanded access and cost savings for stockholders.
• The Board is recommending qualified candidates for election as directors.
• The Audit Committee is comprised solely of independent directors as required by Nasdaq listing standards and the rules and regulations of the SEC.
• The company has a related person transaction policy setting forth the policies and procedures for the identification, review and approval or ratification of related person transactions.

Negatives

• The classification of the Board into three classes with staggered three-year terms may delay or prevent a change of management or a change in control.
• The company previously had a material weakness over financial reporting as a result of the Amended Form 10-K for the year ended December 31, 2021 filed with the SEC on March 31, 2022.

Risks

• The division of the Board into three classes with staggered three-year terms may delay or prevent a change of management or a change in control.
• If stockholders do not ratify the appointment of Ernst & Young LLP, the Board may reconsider the appointment.
• The company faces risks associated with internal control over financial reporting, disclosure controls and procedures, accounting, enterprise risk and legal and regulatory compliance.
• The company faces risks created by the incentives inherent in its compensation policies.

Future Outlook

The company is focused on advancing its clinical programs and pursuing acquisition/partnership opportunities.

Management Comments

• We appreciate your continued support of Orchestra.
• The Board believes that the interests of the Company and its shareholders are best served through a leadership model with a combined Chairperson of the Board and Chief Executive Officer.

Industry Context

The company operates in the medical device and biopharmaceutical industries, facing competition from other companies in these sectors.

Comparison to Industry Standards

• The document mentions several publicly traded companies, including Ligand Pharmaceuticals, Anebulo Pharmaceuticals, Mesoblast Limited, SIGA Technologies, ABIOMED, Motus GI, Corbus Pharmaceuticals Holdings, Opko Health, Abbott Laboratories, St. Jude Medical, Boston Scientific, and Shockwave Medical.
• These companies serve as benchmarks for Orchestra BioMed in terms of market capitalization, product development, and commercialization strategies.
• The document also references Medtronic, a major player in the medical device industry, with whom Orchestra BioMed has a collaboration agreement.

Related Party Transactions

• The company has a lease agreement with Motus GI, where David P. Hochman and Darren R. Sherman previously served on the board of directors.
• The company has a collaboration agreement with Medtronic, which holds more than 5% of the company's common stock.
• Several directors, officers, and greater than 5% beneficial owners purchased Legacy Orchestra capital stock.

Stakeholder Impact

• The outcome of the proposals voted on at the Annual Meeting will impact shareholders.
• The company's performance and strategic decisions will impact employees, customers, and other stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on June 20, 2024.
• The company will continue to advance its clinical programs and pursue acquisition/partnership opportunities.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, Ernst & Young, Stockholders, Voting, Governance, Orchestra BioMed